A recent study compared IgM-index, IgMIF, OCMB, and LS-OCMB and investigated their ability to predict a second relapse in patients with CIS as well as achieving the disability milestones EDSS≥4, EDSS≥6, and conversion to SPMS (40). Here, CD40LG is linked to in situ carcinoma.